Get the Stockscreener App
3.885
0.83%
-0.045
X 4 Pharmaceuticals Inc stock is traded at $3.885, with a volume of 127.53K.
It is down -0.83% in the last 24 hours and down -7.86% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.93
Open:
$3.93
24h Volume:
127.53K
Relative Volume:
0.20
Market Cap:
$366.90M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.8561
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
+5.48%
1M Performance:
-7.86%
6M Performance:
+5.62%
1Y Performance:
+102.46%
1-Day Range:
$3.89
$4.03
1-Week Range:
$3.58
$4.03
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.89 | 371.62M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
489.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
696.80 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.75 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
178.74 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
285.84 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Cash Flow - TradingKey
XFOR|X4 Pharmaceuticals Inc|Price:3.930|Chg%:+0.080 - TradingKey
X4 Pharmaceuticals Inc (XFOR) Balance Sheet - TradingKey
X4 Pharmaceuticals Market Sentiment - Benzinga España
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – FWB:48Q0 - TradingView
XFOR|X4 Pharmaceuticals Inc|Price:3.850|Chg%:-0.140 - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:XFOR - TradingView
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News
Frontier tech research, news & data - MLQ.ai
Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Canada
Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Catalyst Pharma (NASDAQ: CPRX) CSO’s shares and options canceled in merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Form 4 Eton Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Canada
Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Shuttle Pharmaceuticals Inc For: 15 July By Investing.com - Investing.com Canada
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - TradingView
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Eton Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Canada
Form 4 Shuttle Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
XFOR Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentAdjusted Earnings Analysis - dars.gov.et
X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
X4 Pharmaceuticals (XFOR) Registration filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Rallies 11.36% as Positive Sentiment Drives Price Above Key SupportProfit Surge Picks - Bölüm Sonu Canavarı
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Shuttle Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing - ad-hoc-news.de
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
0.24%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):